ChatGPT for Genetic Counselors: 26 AI Prompts That Save Hours on Case Summaries, Variant Letters & CGC Exam Prep

Write a post-session genetic counseling case summary letter. Patient: [age]-year-old [sex], referred by [OB/oncologist/PCP — specify]. Indication: [hereditary breast/ovarian cancer / Lynch syndrome / prenatal / pediatric developmental delay — specify].

Family history: [first- and second-degree relatives with cancer/genetic condition, ages at diagnosis, relationship — or no significant family history].

Genetic testing ordered/resulted: [test name, lab, gene(s), result: pathogenic/VUS/negative — specify].

Variant (if applicable): [gene, variant (HGVS notation), ACMG classification, inheritance pattern].

Letter structure:
(1) Reason for referral and session summary.
(2) Family history review and risk assessment (quantify risk if applicable — BRCAPRO, PREMM5, or empiric recurrence risk).
(3) Genetic testing results with clinical interpretation (ACMG 5-tier: pathogenic / likely pathogenic / VUS / likely benign / benign).
(4) Surveillance and management recommendations per [NCCN / ACMG / ACOG — specify guideline].
(5) Cascade testing recommendation for at-risk relatives.
(6) ICD-10: [Z15.01 BRCA1 / Z15.02 BRCA2 / Z84.81 family history hereditary cancer / specify]; CPT: [96040 genetic counseling / 81162 BRCA1/2 / specify].
(7) Follow-up plan and counselor signature block.
De-identified. NSGC-aligned professional letter format.

Write a variant interpretation report following ACMG/AMP 2015 classification guidelines. Gene: [gene symbol — e.g., BRCA1, MLH1, RET]. Variant: [HGVS notation — e.g., c.5266dupC p.Gln1756Profs*74]. Inheritance: [autosomal dominant / recessive / X-linked — specify].

Report sections:
(1) Variant description: gene function, associated condition(s), inheritance.
(2) Population frequency: [gnomAD allele frequency; 1000 Genomes; absent in controls or reported frequency].
(3) Computational/functional data: [SIFT, PolyPhen-2, CADD score; splicing predictors if applicable; functional studies in literature if available].
(4) Segregation and case data: [ClinVar submissions — pathogenic/conflicting; published case reports; number of probands in literature].
(5) ACMG criteria applied: [list each criterion — PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7 — state met/not met with justification].
(6) Classification: [Pathogenic / Likely Pathogenic / VUS / Likely Benign / Benign].
(7) Clinical significance summary: management implications, re-evaluation timeline if VUS.
ACMG/AMP 2015 framework. ClinGen SVI guidance applied where relevant.

Write a prenatal genetic counseling session note. Patient: [G_P_, age]-year-old, [weeks] gestation, referred for [advanced maternal age / positive cfDNA / abnormal ultrasound / family history — specify].

Screening/diagnostic results:
- cfDNA: [low risk for T21/T18/T13/sex chromosome aneuploidies / high risk — specify trisomy, fetal fraction X%, lab/platform]; OR
- Amniocentesis / CVS: [karyotype 46,XY normal / abnormal — specify result, G-band resolution]; chromosomal microarray: [normal / CNV detected — specify size, classification, inheritance].
- NT measurement: [X.X mm at X weeks — below/above 3.0 mm cutoff]; other ultrasound findings: [specify or none].

Note structure:
(1) Reason for referral and gestational age.
(2) Screening vs. diagnostic testing explanation: residual risk after negative cfDNA; amnio/CVS detection rate and procedure risk (~0.1-0.3% pregnancy loss).
(3) Results review and interpretation: risk framing (absolute risk, NOT just ratios).
(4) Reproductive options discussed: [non-directive — continuing the pregnancy, termination, adoption, neonatal palliative care — confirm all options presented without directive language].
(5) Psychosocial support and referrals offered.
(6) Follow-up: repeat ultrasound, maternal-fetal medicine, neonatology consult if indicated.
ICD-10: [Z36 prenatal screening / O09.52 supervision AMA / specify].

Write a hereditary cancer risk assessment note. Patient: [age]-year-old [sex] with personal/family history of [breast/ovarian/colorectal/endometrial/pancreatic cancer — specify]. Referred by [oncologist / PCP / OB-GYN].

Assessment structure:
(1) Personal history: cancer diagnosis(es), age at diagnosis, bilateral/unilateral, treatment history.
(2) Family history pedigree summary: [3-generation pedigree — maternal/paternal, cancer types, ages at diagnosis, known genetic results in family].
(3) Risk model result: [BRCAPRO: lifetime BRCA1 X% / BRCA2 X%]; [PREMM5 for Lynch: colorectal X% / endometrial X%]; [Tyrer-Cuzick lifetime breast cancer risk: X%].
(4) Genetic testing recommended: [hereditary breast/ovarian cancer panel (CPT 81162 BRCA1/2 or 81432/81433 multi-gene panel); Lynch syndrome panel (CPT 81292/81293/81294/81295/81296 MLH1/MSH2/MSH6/PMS2/EPCAM)].
(5) Result: [pathogenic / VUS / negative — specify gene and variant].
(6) Surveillance recommendations per NCCN 2024:
  - BRCA1/2 pathogenic: annual breast MRI age 25, mammogram age 30, consider risk-reducing mastectomy/salpingo-oophorectomy discussion.
  - Lynch syndrome: colonoscopy every 1-2 years starting age 20-25; endometrial sampling age 30-35.
  - PALB2/CHEK2: risk-stratified per NCCN guidelines.
(7) Cascade testing referrals for first-degree relatives.
ICD-10: [Z15.01 / Z15.02 / Z84.81 — specify]; CPT: [96040 / appropriate panel code].

Write a genetic test order justification note for payer or referring physician communication. Patient: [age]-year-old [sex]. Ordering provider: [genetic counselor under physician supervision / physician — specify].

Test ordered: [test name, lab, CPT code(s) — e.g., BRCA1/2 sequencing + deletion/duplication, CPT 81162; or multi-gene hereditary cancer panel, CPT 81432/81433].

Justification structure:
(1) Clinical indication: [personal history / family history — specify cancers, ages, relationship to patient].
(2) Risk criteria met (cite guideline): [NCCN Genetic/Familial High-Risk: Breast, Ovarian, and Pancreatic v.1.2024 — BRCA testing criteria met; OR NSGC Lynch syndrome testing criteria met — specify which criterion].
(3) Expected clinical impact: test result will directly inform surveillance plan, surgical risk-reduction options, cascade testing for at-risk family members, chemoprevention eligibility.
(4) Insurance coverage language: [payer name] covers CPT [code] when [criterion] is met. Documentation attached: pedigree, risk model output, prior test results.
(5) Alternative testing considered and reason for selection: [single-site vs. panel testing rationale].
Formal justification memo format. NSGC/ACMG guideline citations included.

Write a pediatric genetic evaluation intake summary. Patient: [age]-year-old [sex], referred by [pediatrician / neurologist / neonatologist] for [developmental delay / dysmorphic features / suspected genetic syndrome / abnormal newborn screen — specify].

Summary structure:
(1) Referral reason and chief concern (parent-stated).
(2) Developmental history: milestones (gross motor, fine motor, speech/language, social) — current status vs. age-expected; regression noted: [yes/no].
(3) Medical history: [prenatal exposures, birth history, NICU, surgeries, hospitalizations, current medications].
(4) Family history: [3-generation pedigree — consanguinity, stillbirths, similarly affected relatives, known genetic diagnoses].
(5) Physical exam findings (template for GC to complete): height/weight/OFC percentiles; dysmorphic features checklist [epicanthal folds / low-set ears / micrognathia / clinodactyly / hypotonia / cardiac — specify or none identified].
(6) Differential diagnosis considerations: [chromosomal / single-gene / metabolic / multifactorial — specify top differentials based on phenotype].
(7) Genetic testing plan: [chromosomal microarray CPT 81228/81229; exome sequencing CPT 81415/81416; specific syndrome panel — specify]; newborn screen follow-up if applicable.
(8) Family counseling points: recurrence risk, timeline for results, psychosocial support resources.
ICD-10: [Q99.9 chromosomal abnormality unspecified / F79 unspecified intellectual disability / specify].

Write a letter to a non-genetics referring provider summarizing genetic counseling findings and next steps. Recipient: [OB-GYN / primary care physician / oncologist — specify]. Patient: [age]-year-old [sex], seen for [indication].

Letter structure:
(1) Opening: thank you for referral; one-sentence result summary in plain language.
(2) Key findings (plain language, avoid jargon): what was found, what it means clinically — no HGVS notation in main text; attach formal variant interpretation if needed.
(3) Your action items (bulleted, directive):
  - Order: [specific surveillance tests, referrals — with CPT if helpful].
  - Prescribe: [chemoprevention, risk-reducing medications if applicable].
  - Refer: [to which specialist — surgical oncology, MFM, oncology, cardiology — specify].
  - Educate patient to share results with: [first-degree relatives — specify].
(4) Our action items: cascade testing letters sent to [relatives — or: family letter provided to patient]; variant reclassification notification process explained.
(5) Follow-up: [return to GC in X months / contact us if clinical questions].
(6) GC signature, credentials, NPI, direct contact.
Professional but plain-language tone. NSGC communication standards.

Write a patient education handout about hereditary breast and ovarian cancer (HBOC) syndrome. Reading level: 6th grade. Suitable for print or patient portal. Warm, non-alarmist tone.

Handout sections:
(1) Title: "What Is Hereditary Breast and Ovarian Cancer (HBOC) Syndrome?"
(2) What does it mean? A BRCA1 or BRCA2 gene change was found. Genes are instructions in your cells — a change in BRCA1/2 raises the chance of certain cancers. It does NOT mean you will get cancer.
(3) Your lifetime risk (plain numbers):
  - Average woman: about 12 in 100 chance of breast cancer in her lifetime.
  - BRCA1: about 50-72 in 100. BRCA2: about 45-69 in 100.
  - These are estimates — not certainties. Surveillance and prevention options lower your risk.
(4) What you can do — 3 options explained simply:
  - Watch closely (surveillance): regular breast MRIs, mammograms, gynecologic exams.
  - Medicines (chemoprevention): some medications lower breast cancer risk.
  - Surgery (risk-reducing): some people choose to remove breasts or ovaries. This is your choice — not required.
(5) What about your family? Your blood relatives (parents, siblings, children) may want to be tested. You can share a copy of this handout. Testing is voluntary.
(6) GINA protection: federal law protects you from health insurance and employment discrimination based on genetic test results. Ask your genetic counselor for details.
(7) Resources: FORCE (facingourrisk.org), NSGC (nsgc.org), NCI (cancer.gov).

Write a prior authorization letter for hereditary cancer genetic testing. Patient: [age]-year-old [sex]. Payer: [insurance name, member ID]. Provider: [ordering physician/GC under supervision, NPI].

Test requested: [CPT 81162 — BRCA1/2 full sequencing + deletion/duplication; OR CPT 81432/81433 — hereditary breast/ovarian cancer multi-gene panel; OR CPT 81292-81296 — Lynch syndrome MLH1/MSH2/MSH6/PMS2/EPCAM].

Letter structure:
(1) Patient clinical information: personal history [cancer type, age at diagnosis]; family history [cancers, ages, relationship — 3-generation].
(2) Guideline criteria met (cite specifically):
  - NCCN Genetic/Familial High-Risk Breast/Ovarian v.1.2024, Criterion [specify] — met.
  - OR USPSTF recommendation: referral for genetic counseling for women with family history associated with increased risk for BRCA1/2 variants.
(3) Medical necessity statement: result will directly inform surgical management, chemoprevention eligibility, cascade testing for first-degree relatives, and oncologic surveillance intensity.
(4) Cost-effectiveness: targeted surveillance and prevention based on result avoids costs of unneeded screening in negative patients; enables risk-reducing interventions in positive patients.
(5) Request: approval for CPT [code] at [lab name].
[Physician co-signature, NPI, date]. Formal insurance letter format.

Write a patient communication about GINA (Genetic Information Nondiscrimination Act) and HIPAA genetic information protections. Plain language. Suitable for pre-test counseling or patient packet.

Template sections:
(1) What is GINA? The federal Genetic Information Nondiscrimination Act (GINA, 2008) makes it illegal for:
  - Health insurers (Title I) to use genetic test results to deny coverage, set premiums, or impose pre-existing condition exclusions.
  - Employers with 15+ employees (Title II) to use genetic information in hiring, firing, pay, or job assignments.
(2) Important GINA limitations — what GINA does NOT cover:
  - Life insurance, disability insurance, and long-term care insurance (NOT covered by GINA). Consider this before testing if these are concerns.
  - Employers with fewer than 15 employees.
  - U.S. military.
(3) HIPAA protections: Your genetic information is protected health information (PHI). Labs and healthcare providers cannot share your results without written authorization (with exceptions for treatment, payment, operations).
(4) Your rights: You may request a copy of your genetic test results. Results belong to you. You decide who can access them.
(5) State protections: many states have additional protections beyond federal GINA — ask your genetic counselor about [state] law.
(6) Questions? Contact: [genetic counselor name, credentials, phone, email].

Write a cascade testing family letter for a patient (proband) to share with at-risk relatives. Variant found in proband: [gene — e.g., BRCA1, MLH1, CHEK2], [classification — pathogenic/likely pathogenic]. Patient relationship to recipient: [parent / sibling / adult child — specify].

Letter (from proband's perspective, written by GC for patient to sign/send):

"Dear [Family Member Name / 'My dear family'],

I recently had genetic testing and was found to carry a [pathogenic/likely pathogenic] variant in the [gene] gene. This means I have an increased risk for [hereditary breast and ovarian cancer / Lynch syndrome-related cancers — specify].

Because this gene change can run in families, you may have a 50% chance of carrying the same variant. Having this information lets you make choices about your own health.

What I'd encourage you to do:
- Talk to your doctor or a genetic counselor about getting tested for the specific variant [gene: variant — include HGVS notation].
- Single-site testing (testing only for my specific variant) is simpler and usually less expensive than full gene sequencing.
- A positive result means higher cancer risk and more surveillance options. A negative result means you did not inherit my variant and have average population risk.

This is your choice — there is no pressure to be tested. If you would like a referral to a genetic counselor, you can contact NSGC Find a Genetic Counselor at nsgc.org/findagc or ask your doctor.

[Patient name / 'Your family member']"

GC cover note: include lab name, variant notation, single-site CPT code, and NSGC referral resource.

Write a genetic counselor's summary contribution to a multidisciplinary tumor board (MTB) or molecular tumor board. Patient: [age]-year-old [sex], tumor type: [breast / colorectal / endometrial / pancreatic / other — specify].

GC summary for tumor board:
(1) Germline testing status: [completed / pending / declined — specify]. Result: [pathogenic / VUS / negative — gene, variant, ACMG classification].
(2) Somatic-germline correlation: tumor's somatic variant report shows [somatic BRCA1/2 mutation / MSI-H / TMB — specify] — germline status [concordant / discordant / unknown]. Implications for germline testing recommendation.
(3) Hereditary syndrome assessment: personal/family history review — [Lynch syndrome criteria met per Bethesda / PREMM5 / Amsterdam II; HBOC criteria met per NCCN — specify or not met].
(4) Therapeutic implications of germline result:
  - BRCA1/2 pathogenic: PARP inhibitor eligibility (olaparib/niraparib/rucaparib — FDA-approved indications).
  - MLH1/MSH2/MSH6/PMS2 pathogenic: pembrolizumab MSI-H indication; Lynch syndrome surveillance protocol.
(5) Family implications: cascade testing recommended for [first-degree relatives — specify]; family letter [provided / pending].
(6) Recommended follow-up: [return GC appointment, timing; variant reclassification monitoring plan].
MTB-appropriate format. NSGC/ACMG/ASCO clinical utility framework.

Create a domain-weighted study guide for the ABGC genetic counseling board exam. Use the official ABGC blueprint:
- Genetic Counseling Practice: 40%
- Genetic/Medical Knowledge: 35%
- Professional Issues: 25%

Study guide format:
(1) Domain 1 — Genetic Counseling Practice (40%): key topics: intake/pedigree construction, risk assessment communication, psychosocial assessment (GARF, adaptation models), informed consent, non-directiveness vs. autonomy, crisis counseling, multicultural competency. High-yield: 3-generation pedigree symbols (NSGC standards), recurrence risk framing (absolute vs. relative), psychological adaptation models (Lippman-Hand & Fraser, Shiloh). Exam tip: scenario questions test process over content.
(2) Domain 2 — Genetic/Medical Knowledge (35%): key topics: Mendelian inheritance, chromosomal disorders, molecular genetics, cancer genetics, prenatal genetics, newborn screening, pharmacogenomics. High-yield: Hardy-Weinberg equilibrium calculations, LOD score interpretation, ACMG variant classification 5-tier, sensitivity/specificity of prenatal screens, FISH vs. microarray vs. sequencing indications.
(3) Domain 3 — Professional Issues (25%): key topics: ethical principles (autonomy, beneficence, non-maleficence, justice), GINA/HIPAA, scope of practice, supervision/licensure, NSGC Code of Ethics, duty to warn third parties (Safer v. Pack).
(4) 8-week study schedule with weekly priorities by domain weight.
(5) 5 high-yield mnemonics for frequently tested concepts.

Generate 3 ABGC-style genetics knowledge practice questions with complete rationale. Cover these 3 topics:

Question 1 — Hardy-Weinberg Equilibrium: Write a calculation question using carrier frequency or disease prevalence. Include 4 answer choices, correct answer marked, and full rationale explaining the HWE formula (p^2 + 2pq + q^2 = 1), the steps to solve, and the common exam trap (confusing q vs. q^2 when carrier frequency is given vs. disease prevalence).

Question 2 — LOD Score Interpretation: Write a linkage analysis question involving LOD score threshold interpretation. Include 4 answer choices, correct answer, and rationale explaining: LOD >=3.0 = evidence of linkage (odds 1000:1 in favor), LOD <=-2.0 = evidence against linkage, and why 3.0 is the accepted threshold. Common trap: confusing LOD score of 3.0 meaning "3.0" vs. "10^3.0 = 1000:1 odds."

Question 3 — ACMG Variant Classification Trap: Write a question about a VUS (variant of uncertain significance) and appropriate counseling. Include 4 answer choices, correct answer, and rationale covering: VUS does not guide clinical management the same as pathogenic; patients should NOT make irreversible surgical decisions based on VUS alone; VUS reclassification occurs over time and patients should be re-contacted. Common trap: selecting the same management as pathogenic for a VUS.

Generate 3 ABGC-style genetic counseling skills practice questions with complete rationale. Cover these 3 topics:

Question 1 — Informed Consent: A patient is about to undergo exome sequencing and asks: "Will this test tell me if I'll get Alzheimer's?" Write a question about the counselor's BEST response demonstrating informed consent for secondary findings. Include 4 answer choices, correct answer, and rationale covering: ACMG SF v3.2 secondary findings policy; patient right to opt in/out of secondary finding categories; GC role in pre-test counseling for variants unrelated to the primary indication.

Question 2 — Psychological Adaptation: A patient who received a BRCA1 pathogenic result 2 weeks ago calls crying and says she cannot stop thinking about dying. Write a question about the MOST appropriate GC response. Include 4 answer choices, correct answer, and rationale covering: Lippman-Hand & Fraser adaptation model phases (impact, denial, equilibrium); acute distress vs. crisis requiring immediate referral; empathic reflection vs. information-giving timing.

Question 3 — Non-Directiveness vs. Patient Autonomy: A patient with a fetus diagnosed with Down syndrome asks the genetic counselor: "What would YOU do?" Write a question about the BEST response. Include 4 answer choices, correct answer, and rationale covering: non-directiveness as NSGC core value; distinction between non-directiveness and withholding information; patient autonomy — all options are presented fully and without coercion.

Create an evidence-based practice quick-reference card for genetic counselors covering 3 key NSGC/ACMG/ACOG guidelines.

Format: concise bullet table for each guideline — indication, recommended test, criteria, and key caveat.

Topic 1 — BRCA1/2 Testing (NCCN Genetic/Familial High-Risk: Breast, Ovarian, and Pancreatic v.1.2024):
- Who to test: personal history criteria: breast cancer <=45, triple-negative <=60, Ashkenazi Jewish ancestry, >=2 first-degree relatives with breast/ovarian cancer, male breast cancer, ovarian cancer any age, pancreatic cancer with >=1 affected relative.
- Test: BRCA1/2 full sequencing + del/dup (CPT 81162) or multi-gene panel (CPT 81432/81433).
- Key caveat: negative panel does not eliminate hereditary risk — residual risk from uncharacterized genes; clinical judgment remains essential.

Topic 2 — Lynch Syndrome Testing (NSGC/ACMG/NCI):
- Who to test: Amsterdam II criteria; Bethesda guidelines; universal tumor testing for all colorectal and endometrial cancers (IHC + MSI reflex); PREMM5 >=2.5%.
- Test: MLH1/MSH2/MSH6/PMS2/EPCAM sequencing + del/dup (CPT 81292-81296); IHC + MSI as reflex.
- Key caveat: MLH1 hypermethylation (somatic, not germline) accounts for most MSI-H/MLH1-absent colorectal tumors — BRAF V600E testing differentiates before germline testing.

Topic 3 — Prenatal cfDNA Screening (ACOG/SMFM 2020 + USPSTF 2023):
- Who to offer: all singleton pregnancies regardless of age.
- What it detects: T21, T18, T13, monosomy X, other sex chromosome aneuploidies; some platforms include 22q11.2 deletion.
- Key caveat: screening, NOT diagnostic — positive cfDNA requires diagnostic confirmation (amniocentesis or CVS). False positives occur, especially for T18/T13 in low-risk patients. Fetal fraction <4% = non-reportable result.

Create a 50-hour 5-year ABGC continuing education recertification plan for a CGC specializing in [prenatal + hereditary cancer — or specify your area]. ABGC requirement: 50 CE hours every 5 years; minimum 20 hours in genetics/genomics; maximum 10 hours in any single category.

CE Plan (table by year, activity, hours):

Year 1 (10 hrs):
- NSGC Annual Education Conference: 6 hrs genetics/genomics CE (Category 1 — largest annual GC conference).
- ACMG Annual Clinical Genetics Meeting: 4 hrs genetics CE (variant interpretation and precision medicine focus).

Year 2 (10 hrs):
- NSGC online CE modules: 5 hrs (nsgc.org — cancer genetics, prenatal, equity modules available).
- Journal CE: American Journal of Human Genetics / Genetics in Medicine self-study: 5 hrs.

Year 3 (10 hrs):
- State GC symposium or regional NSGC affiliate meeting: 4 hrs.
- ABGC-approved webinar series (variant interpretation, pharmacogenomics): 6 hrs.

Year 4 (10 hrs):
- Hospital or university grand rounds with CE credit: 4 hrs.
- Peer-reviewed case presentation / poster at NSGC conference: 6 hrs (active participation category).

Year 5 (10 hrs):
- NSGC Annual Conference: 6 hrs.
- Ethics, supervision, or health equity CE modules: 4 hrs (Professional domain coverage).

Total: 50 hrs | >=20 hrs genetics/genomics | <=10 hrs any single category. Track in ABGC CE portal. Renewal deadline: [5-year CGC anniversary date].

Generate 3 mock oral board question-and-answer scenarios for ABGC certification preparation. Cover psychosocial and ethical dimensions. For each scenario:
- State the scenario (2-3 sentences)
- Provide the model answer (4-6 bullet points — key points an examiner would expect)
- Note 1-2 common mistakes candidates make

Scenario 1 — DUTY TO WARN: A patient tests pathogenic BRCA1. She refuses to inform her adult daughter. Her daughter is your patient in a separate practice. What do you do?
Model answer bullets: respect for patient autonomy vs. duty to warn/protect; Safer v. Pack established limited duty to warn identifiable at-risk relatives; NSGC Code of Ethics prioritizes patient autonomy but permits disclosure to prevent serious harm; consult ethics board and legal counsel before any action; document counseling thoroughly; offer patient support to disclose voluntarily.
Common mistakes: acting immediately without consultation; automatically disclosing without ethical/legal review.

Scenario 2 — PRENATAL PATIENT IN CRISIS: A patient calls after a T21 diagnosis, states she cannot make a decision and her husband is pressuring her to terminate. What do you do?
Model answer bullets: assess safety from coercive partner (domestic violence screening if indicated); provide non-directive counseling — all options, patient's own values centered; offer time extension; refer to social work/therapist; provide written information on all options including palliative care teams and Down syndrome support organizations.
Common mistakes: assuming patient wants termination; failing to address partner coercion.

Scenario 3 — VUS COUNSELING: A patient with strong family history tests VUS in BRCA1. She wants prophylactic bilateral mastectomy. How do you counsel?
Model answer bullets: clearly explain VUS ≠ pathogenic — surgical decisions based on VUS are not guideline-supported; explore patient's fear and family experience; do NOT be directive either way; recommend multidisciplinary consultation; emphasize re-contact plan for VUS reclassification; document session thoroughly.
Common mistakes: validating prophylactic surgery for VUS without thorough exploration; being directive without exploring patient values.

Write an annual CGC performance self-evaluation with SMART goals for a genetic counselor in a [university hospital / cancer center / prenatal practice — specify] setting.

Self-evaluation structure:
(1) Clinical performance summary:
  - Caseload throughput: [X patients/week; case mix breakdown — % prenatal, % hereditary cancer, % pediatric]; benchmark vs. program average or NSGC survey.
  - Documentation quality: case summary turnaround time — target <=5 business days; current average: [X days]; initiative to improve: [EHR template, prompt library].
  - Patient satisfaction: [CAHPS or internal scores — describe].

(2) SMART Goals for next year (3 goals):
  - Goal 1 — Caseload throughput: Increase from [X] to [X] patients/week by [date] by implementing structured EHR documentation templates, measurable by monthly caseload reports.
  - Goal 2 — VUS reclassification protocol: Establish a 6-month lab re-contact protocol for all active VUS patients by [date]; measurable by tracking re-contact rate in departmental VUS registry.
  - Goal 3 — Health equity metric: Complete 1 CE course in culturally responsive genetic counseling and implement language-concordant patient education materials for the [Spanish/Somali/other — specify] population served by [date]; measurable by patient language preference documentation rate improvement.

(3) Professional development: CE hours completed this cycle [X/50]; conference presentations/publications if applicable; supervision hours if pursuing board-approved supervisor status.

(4) Areas for growth and supervisor support requested.
NSGC Scope of Practice and ABGC professional competencies framework.

Write a variant reclassification notification letter for a patient and their provider. Prior classification: [VUS / likely benign / likely pathogenic — specify]. New classification: [pathogenic / likely pathogenic / benign / likely benign — specify]. Gene: [gene]. Variant: [HGVS notation].

Patient letter:
(1) Opening: explain that genetic labs periodically review variant classifications as new information becomes available.
(2) What changed: "[Variant] in the [gene] gene was previously classified as [prior classification]. Based on new evidence [published research / ClinVar submissions / functional data — specify], it has been reclassified as [new classification]."
(3) What this means for you:
  - If upgrade (VUS to pathogenic/LP): "This change means your result is now considered clinically significant. Please contact your genetic counselor or physician to discuss updated surveillance and management recommendations."
  - If downgrade (pathogenic/LP to VUS/benign): "This change means the variant no longer explains your increased cancer risk from a genetic testing standpoint. Please discuss with your genetic counselor what this means for your ongoing care."
(4) Action required: call [GC name, phone] to schedule a follow-up appointment within [X weeks].
(5) Family notification: if reclassified to pathogenic — relatives who tested negative for this variant may need re-contact; GC to coordinate.

Provider letter: same key points in clinical language with ACMG classification change summary and updated management recommendation per current guidelines. Include updated ICD-10 code if classification changes.

Write a PDSA (Plan-Do-Study-Act) quality improvement proposal for a genetic counseling program. Choose one aim:

OPTION A — Variant Interpretation Letter Turnaround Time:
Problem statement: Average turnaround time for variant interpretation letters is [X business days]; program target is <=5 business days; gap: [X - 5] days.
AIM: Reduce variant interpretation letter turnaround time from [X] to <=5 business days for >=80% of cases by [date].
PLAN: Root cause analysis — [EHR template burden, variant classification research time, provider review bottleneck — specify]. Intervention: [structured ChatGPT-assisted documentation workflow / EHR smart text / pre-approved template library — specify].
DO: Pilot intervention with [X GCs / X cases] over [8 weeks].
STUDY: Measure: turnaround time per letter (days from result receipt to letter finalized); % <=5 days. Baseline vs. post-pilot comparison.
ACT: If successful — implement program-wide; if mixed — refine template; if unsuccessful — identify new barrier.

OPTION B — Cascade Testing Uptake Rate:
Problem statement: Estimated [X%] of at-risk first-degree relatives of identified BRCA/Lynch pathogenic carriers complete testing within 12 months; program target >=50%.
AIM, PLAN, DO, STUDY, ACT in same format targeting cascade testing uptake.

Format as a 1-page QI proposal suitable for department or hospital quality committee submission. SQUIRE 2.0 framework elements.

Write a scope-of-practice clarification memo for a genetics team, distinguishing roles between CGC (Certified Genetic Counselor), MD medical geneticist, and genetic nurse counselor (GNC). Purpose: clarify referral matrix and reduce scope confusion in a multidisciplinary genetics program.

Memo format:

TO: Genetics Program Staff and Referring Providers
FROM: [GC Program Director name]
RE: Genetics Team Roles and Referral Matrix

Role Definitions (brief):
- CGC (MS, CGC): Board-certified genetic counselor — genetic counseling, risk assessment, pedigree construction, pre/post-test counseling, patient education, care coordination. Works under physician collaboration agreement in most states.
- MD Geneticist (MD/PhD, FACMG): Board-certified clinical geneticist — diagnoses genetic conditions, manages complex syndromic presentations, orders and interprets complex diagnostics, prescribes treatment. Required for: dysmorphology evaluations, inborn errors of metabolism, complex multi-system genetic disorders.
- Genetic Nurse Counselor (RN, APNG): Registered nurse with genetics specialty training — patient education, care navigation, follow-up coordination, may provide pre/post-test counseling depending on state licensure and institution credentialing.

Referral Matrix (table format):
| Indication | Primary Role | When to Escalate to MD |
|---|---|---|
| Hereditary cancer risk counseling | CGC | Complex syndrome, metabolic concern, pediatric diagnosis |
| Prenatal counseling (cfDNA/amnio) | CGC | Fetal structural anomaly with syndromic concern |
| Pediatric developmental delay | MD Geneticist (CGC assists) | All complex cases |
| VUS counseling | CGC | If management decision unclear |
| Rare/undiagnosed disease | MD Geneticist | All |

Questions: contact [program director name, contact info].

Write two versions of a cover letter for a Certified Genetic Counselor (CGC) with [X years] of experience in [prenatal / hereditary cancer / both — specify].

VERSION A — Academic Medical Center (AMC) / University Hospital:
Tone: collaborative, mission-driven, research-aware.
Opening: specific to the institution's genetics program; reference a faculty member's research or program focus if known.
Body paragraphs:
- Clinical expertise: caseload breadth, patient populations served, documentation efficiency, complex variant counseling experience.
- Teaching/supervision: supervised students, presented at grand rounds, contributed to educational curriculum if applicable.
- Research interest: alignment with institution's research priorities (variant interpretation equity, prenatal outcomes, precision oncology — specify).
Closing: express interest in contributing to the program's mission; request interview.

VERSION B — Commercial Lab / Biotech / Direct-to-Consumer (DTC):
Tone: results-oriented, scalable-thinking, industry-aware.
Opening: specific to the company's product, platform, or pipeline.
Body paragraphs:
- Clinical translation experience: explaining complex genomic results to diverse patients and non-genetics providers; variant interpretation expertise.
- Scalability thinking: documentation efficiency, template development, throughput metrics.
- Business awareness: patient/provider satisfaction, turnaround time metrics, experience with laboratory result portals or EHR integrations.
Closing: express interest in contributing to the company's clinical mission and patient impact at scale.

Each version: 3 tight paragraphs, <=350 words. CGC credentials, NPI, and contact info in header.

Write LinkedIn headline and summary copy for a CGC in two professional tracks.

TRACK 1 — Clinical Genetic Counselor (hospital / academic / clinic):
Headline options (choose 1):
- "Certified Genetic Counselor (CGC) | Hereditary Cancer + Prenatal | [Hospital/City]"
- "CGC | BRCA/Lynch/Prenatal Genetic Counseling | [X] Years | [Specialty focus]"
Summary (150 words max):
- Opening hook: patient impact statement — how you change outcomes for patients facing a hereditary cancer diagnosis or prenatal uncertainty.
- Clinical scope: patient populations, case volume, variant interpretation expertise, multidisciplinary team roles.
- Certifications: CGC (ABGC), state licensure, NSGC member.
- Invitation: open to [network connections / speaking / student mentorship].

TRACK 2 — Lab / Industry / Biotech Genetic Counselor:
Headline options (choose 1):
- "Genetic Counselor | Clinical Genomics | Variant Curation + Lab Interpretation | [Company/City]"
- "CGC | Lab Genetic Counseling | Precision Oncology | [X] Years Industry Experience"
Summary (150 words max):
- Opening hook: your role in translating genomic complexity into actionable clinical intelligence.
- Industry scope: variant curation experience, lab portal/EHR integration, provider education at scale, ACMG variant classification.
- Value proposition: documentation efficiency, scalable counseling workflows, cross-functional team collaboration (clinical, bioinformatics, medical affairs).
- Invitation: open to [connections in genomics / precision medicine / DTC].

Write a personal statement for a Certified Genetic Counselor (CGC) applying to a PhD or ScD program in [human genetics / genetic counseling / genomic medicine / public health genomics — specify]. Applicant background: [X years clinical experience as CGC, specialty: prenatal/cancer, current institution, relevant research experience if any].

Personal statement structure (750 words max, tight):
(1) Opening narrative (no clichés): a specific patient encounter or clinical observation that exposed a gap in knowledge or equity — the moment that crystallized the research question. Keep to 3-4 sentences.
(2) Research focus and rationale (choose one framing):
  - VARIANT INTERPRETATION EQUITY: how ACMG variant classification relies on population databases (gnomAD) underrepresented for non-European ancestry populations — resulting in higher VUS rates for patients of color; your clinical observation of this disparity; specific gap you want to address.
  - PATIENT COMMUNICATION RESEARCH: how genetic counseling communication affects patient decision-making and psychological outcomes; specific gap in prenatal or cancer counseling communication research; how your clinical experience informs the research question.
  - PRECISION ONCOLOGY FRAMING: how germline-somatic interactions in hereditary cancer are undertreated due to GC workforce gaps; the pipeline from GC-identified variants to tumor board actionability; research question you want to pursue.
(3) Research training and skills: relevant coursework, supervision of students, any publications or presentations; statistical skills; exposure to variant interpretation databases or laboratory.
(4) Why this program: specific faculty members, research groups, and institutional resources — not generic.
(5) Career goal: how the PhD/ScD advances your ability to improve patient outcomes, close equity gaps, or translate genomic research into clinical practice at scale.

Write a salary negotiation script and supporting analysis for a Certified Genetic Counselor, using NSGC Professional Status Survey benchmarks.

NSGC 2022 Professional Status Survey Benchmarks (approximate):
- Entry-level CGC (0-2 years): $65,000-$80,000
- Mid-level CGC (3-7 years): $75,000-$95,000
- Senior CGC (8+ years): $90,000-$115,000+
- Setting premium: academic medical center/comprehensive cancer center typically $5-$15K above community hospital; commercial lab/biotech often $10-$20K above clinical.
- Specialty premium: cancer genetics specialist — $5-$10K above prenatal average.
- Supervisory/program director differential: $10,000-$20,000+ above staff CGC.
- Geographic adjustment: Seattle/NYC/SF/Boston — 15-25% above national median; Midwest/Southeast — at or below median.

Negotiation script:
(1) Research anchor: "Based on the NSGC 2022 Professional Status Survey for a CGC with [X years] of experience in [specialty] in [city/region], the median compensation range is [$X-$X]."
(2) Value statement (1-2 sentences): specific clinical value you bring — caseload capacity, variant interpretation depth, documentation efficiency, supervisory experience.
(3) Ask: "Based on my experience and the market data, I'm targeting a base salary of $[X — top of fair range]."
(4) Handling pushback: counter with signing bonus / additional CE budget / extra PTO / flexible scheduling — rank your priorities.
(5) Written offer follow-up template: brief thank-you + restatement of agreed terms.

Note: Always confirm current NSGC survey data at nsgc.org/professionalstatussurvey before negotiating — ranges update annually.